SCHEMBL13577005

SCHEMBL13577005

CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc(Cl)c(N)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ HSD17B1 P14061 4/20 0.46
▸ HSD17B2 P37059 4/20 0.46
▸ MAPT P10636 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ LMNA P02545 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TP53 P04637 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ GPR27 Q9NS67 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577009 0.88 ALDH1A1 (0.56) KDM4EHSD17B1HSD17B2MAPTALDH1A1
SCHEMBL5467219 0.87 KDM4E (0.56) PGRKDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL13577037 0.86 PSEN1 (0.46) PGRKDM4EHSD17B1HSD17B2MAPT
SCHEMBL13577036 0.84 PGR (0.52) PGRKDM4EHSD17B1HSD17B2ALDH1A1
SCHEMBL30270588 0.84 HSD17B1 (0.49) PGRKDM4EHSD17B1HSD17B2MAPT
SCHEMBL13577029 0.84 MAPT (0.44) PGRKDM4EHSD17B1HSD17B2MAPT
SCHEMBL25920645 0.84 HSD17B1 (0.49) PGRKDM4EHSD17B1HSD17B2MAPT
SCHEMBL13577030 0.84 PGR (0.52) PGRKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL13577041 0.82 PSEN1 (0.46) PGRKDM4EMAPTLMNASMN1; SMN2
SCHEMBL10300188 0.81 ESR1 (0.41) PGRKDM4EMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 — — US disclosed
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 — — US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 — — US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF SHBG, CYP19A1, NR5A1 PGR 123/4885KDM4E 930/4885HSD17B1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback